AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03135665 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.~Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.~SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral.
Study NCT03841097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Tacrolimus Tablets
Description: The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
Study NCT03841097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Tacrolimus Capsule
Description: The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12-24 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
Study NCT02492958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus 4-antigen vaccine
Description: a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
Study NCT02492958 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
Study NCT01412138 — intervention group
Intervention type: OTHER
Intervention: genetic analysis
Description: 1. To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.~2. In vitro culture conditions for cell proliferation.~3. To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.~4. Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group.
Study NCT04113655 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pertagen (aP BioNet)
Description: Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202.
Study NCT04464135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acetic acid staining
Description: The water exchange colonoscopy is used during insertion procedure, in which the water contains 1% acetic acid, and the liquid is absorbed during the withdrawal process for observation.
Study NCT04464135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange colonoscopy
Description: The water exchange colonoscopy is used during insertion procedure, and the liquid is absorbed during the withdrawal process for observation.
Study NCT00672854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic 20% Intravenous Emulsion
Description: ClinOleic 20% is a lipid emulsion containing a mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to an essential fatty acid intake of approximately 20% of the total fatty acids intake.
Study NCT04113655 — intervention group
Intervention type: BIOLOGICAL
Intervention: Boostagen (TdaP BioNet)
Description: Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202.
Study NCT04113655 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adacel
Description: Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202
Study NCT04092725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAB
Description: Single oral 150-mg dose of DAB on Day 1 AM.
Study NCT04092725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078 plus DAB
Description: Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
Study NCT02380222 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Single interview lasting approximately one hour
Study NCT00941798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149 Twisthaler®
Description: Once daily via multi-dose dry-powder inhaler
Study NCT00941798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Twisthaler®
Description: Once daily via multi-dose dry-powder inhaler
Study NCT04453423 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anlotinib + Pemetrexed+Carboplatin
Description: Anlotinib: 12mg, QD, PO, d1-14, 21 days per cycle~Carboplatin: AUC 5 on day 1 of 21 days per cycle~Pemetrexed: 500mg/m2 iv on day 1 of 21 days per cycle
Study NCT04453423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)
Study NCT04453423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Pemetrexed
Description: Anlotinib:12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)~Pemetrexed:500mg/m2 iv on day 1 of 21 days per cycle(maintenance phase)
Study NCT04453423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg, QD, PO, d1-14, 21 days per cycle(maintenance phase)
Study NCT03547492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Talking
Description: Written packet including 8 lessons: What's My Corrected Age, Watch Me Learn (language milestones in the 1st year of life), Reading Aloud, Sing-a-long: Sleepy Songs, Sing-a-long: Alert Songs, Copying First Sounds, Playing Games, Talk to Your Baby.
Study NCT03547492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA recordings-language
Description: LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, after reviewing Teaching Talking and linguistic feedback of first recording, 4 and 12 months of age. Participants are mailed feedback of their 2nd, 4 and 12 month recordings.
Study NCT03547492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LENA recordings-motor
Description: LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, 2nd, 4 and 12 months of age. Participants are mailed feedback on recordings after completing study.
Study NCT03547492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastering Movement
Description: A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...
Study NCT03547492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mastering Movement
Description: A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...
Study NCT03547492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language text messages
Description: 12 weekly text messages. Each is 1-2 sentences to review concepts of Teaching Talking
Study NCT03547492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor text messages
Description: 4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement
Study NCT03547492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor text messages
Description: 4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement
Study NCT01691625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy plus DC-CIK immunotherapy
Description: Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period.
Study NCT01691625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation only
Description: Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.
Study NCT03960489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Participants will receive single dose of 100 mg azo dye free tablet or mini tablet suspension or solid mini tablet or dye containing tablet.
Study NCT05514080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Insulin closed-loop
Description: 41-hour intervention period in which the participants are treated with rapid insulin in the closed-loop system.
Study NCT01569659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone
Description: 80 mg/day for up to 30 weeks
Study NCT01569659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Up to 240 mg/day for up to 30 weeks
Study NCT02093325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
Study NCT02093325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
Study NCT02165332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: SAD RO7033877
Description: Single dose
Study NCT02165332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 1: SAD placebo
Description: Single dose
Study NCT02165332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Treatment A, RO7033877
Description: Single dose RO7033877 and moxifloxacin placebo
Study NCT02165332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Treatment B, RO7033877
Description: Single dose RO7033877 and moxifloxacin placebo
Study NCT02165332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Treatment C, moxifloxacin
Description: Single dose moxifloxacin and RO7033877 placebo
Study NCT02165332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Treatment D, RO7033877 and moxifloxacin placebo
Description: Single dose moxifloxacin placebo and RO7033877 placebo
Study NCT02310022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Omega 3
Description: 4 g (4 capsules) once a day, administered with food
Study NCT02310022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Omega-3 Comparator
Description: 4 g (4 capsules) once a day, administered with food
Study NCT02981901 — intervention group
Intervention type: OTHER
Intervention: Patient with ovarian epithelial cancer
Study NCT01696448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CAR-191
Description: Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
Study NCT01696448 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
Study NCT03661502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VVV
Description: ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
Study NCT03661502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCV
Description: ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
Study NCT04653441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child-Caregiver-Advocacy-Resilience [ChildCARE] intervention
Description: The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy).
Study NCT01793025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATAC Therapy
Description: Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
Study NCT02228954 — intervention group
Intervention type: PROCEDURE
Intervention: Molecular imaging
Study NCT05296499 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test (CPET)
Description: Cardiopulmonary exercise testing using cycle ergonomenter
Study NCT05296499 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise cardiac MRI
Description: Exercise cardiac MRI using supine cycle, participants exercised to peak workload as determined by CPET
Study NCT05296499 — intervention group
Intervention type: OTHER
Intervention: 6 minute walk test
Description: 6MWT
Study NCT05296499 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: FBC, U\&E, LFTS
Study NCT05296499 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: SF36, EQ5D, VEINES-QoL/Sym
Study NCT05296499 — intervention group
Intervention type: OTHER
Intervention: Repeat baseline assessments
Description: repeat baseline
Study NCT05296499 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR venogram
Description: MRI scan of venous system
Study NCT04248647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: This arm will receive a 4-week prehabilitation program consisting of:~Exercise: Participants will receive a 3x/week aerobic and strength training exercise program. They will perform 2 workouts per week at home and attend an in-hospital supervised exercise session once per week.~Nutritional counselling: Participants will meet with a registered dietician who will provide personalized nutritional recommendations and a whey protein supplement, tailored according to participants' self-reported dietary intake and anthropometric measurements.~Psychological support: Participants will receive a 90-minute session at baseline, and weekly in-hospital follow-ups throughout the preoperative period. The sessions will aim to reduce preoperative distress and improve adherence to the exercise program and nutritional recommendations. Psychological support will be delivered by a trained master's student, under the direct supervision of a registered Clinical Psychologist.
Study NCT02149784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of primary tumor
Description: Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy'
Study NCT04654039 — intervention group
Intervention type: OTHER
Intervention: Other: Non intervention
Description: Non intervention
Study NCT01521962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT01521962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin injection
Study NCT00426725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EasyLabour
Description: According to the trial protocol
Study NCT00426725 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: EasyLabour
Description: According to the trial protocol
Study NCT00946335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Given PO
Study NCT00946335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT00946335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00946335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02843256 — intervention group
Intervention type: DEVICE
Intervention: Isomark Canary
Description: The Isomark Canary will analyze the exhaled air and generate a breath delta value.
Study NCT01106443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Thyroidectomy + CLND
Description: Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.
Study NCT01106443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy - CLND
Description: Removal of all possible thyroid tissue without dissection of neck level 6.
Study NCT01106443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemi-thyroidectomy + CLND
Description: Removal of one thyroid lobe and ipsilateral central lymph nodes
Study NCT01106443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemi-thyroidectomy - CLND
Description: Removal of one thyroid lobe only. No lymphatic dissection.
Study NCT02073461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD1579 2.5%
Study NCT02073461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD1579 5%
Study NCT02073461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT01612325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium-166 polylactic microspheres
Description: Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
Study NCT00583622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg by vein daily over 90 minutes for 2 Days
Study NCT00583622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 333 mg/m\^2 by vein over 2 hours for 3 Days
Study NCT00583622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 300 mg/m\^2 by vein over 2 hours for 1 Day
Study NCT00583622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,800 mg/m2 by vein over 3 hours for 4 Days
Study NCT00583622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 50 mg/m\^2 by vein over 15 minutes for 3 Days